<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01206322</url>
  </required_header>
  <id_info>
    <org_study_id>1R21-DK088446301</org_study_id>
    <nct_id>NCT01206322</nct_id>
  </id_info>
  <brief_title>Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes</brief_title>
  <official_title>Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Boston Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our goal is to determine the acute effects of intranasal insulin on regional perfusion and
      cognition of older adults. We propose a pilot study to examine the effect of a single dose of
      intranasal insulin on regional vasoreactivity and cognitive functions in 30 subjects with
      T2DM and 30 healthy controls &gt;50 years old using a double blinded, placebo-controlled,
      cross-over design.

      Hypothesis 1: Intranasal insulin improves acutely regional perfusion and vasoreactivity in
      older patients with T2DM as compared with placebo and compared with the control group.

      Hypothesis 2: Intranasal insulin improves cognitive functioning including attention, memory
      and executive function in diabetic patients as compared with placebo and compared with
      control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes mellitus (T2DM) is a major risk factor for vascular dementia. DM alters
      insulin transport across blood-brain barrier affecting perfusion and neuronal function.
      Intranasal administration enables effective delivery of insulin to the brain. Clinical
      studies demonstrated improvement of cognitive function and memory in healthy and cognitively
      impaired people.

      Aim 1: To determine the acute effects of a single 40-IU dose of intranasal insulin vs.
      placebo on regional perfusion and vasoreactivity to CO2 challenge measured by 3-D continuous
      arterial spin labeling (CASL) MRI at 3 Tesla in the control and diabetic groups. We will use
      transcranial Doppler to determine the effects on intranasal insulin vs. placebo on cerebral
      autoregulation based on measurements of beat-to-beat pressure flow velocity relationship.

      Aim 2: To determine whether intranasal insulin improves cognitive functioning in older T2DM
      patients as compared with placebo and the control group.

      This translational study will address an important area about the effects of intranasal
      insulin on cerebral blood flow regulation and cognition in older diabetics that has not been
      studied. Intranasal insulin administration may provide a novel therapeutic target for
      prevention and treatment of microvascular disease and cerebrovascular complications of T2DM.
      If successful, this approach may have significant impact on the clinical management of large
      population of older adults with T2DM.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Outcome: Brief Visuospatial Spatial Memory Test -Total Recall (Unit T Score)</measure>
    <time_frame>Acute changes within 2 hours</time_frame>
    <description>To determine the acute effects of a single 40-IU dose of intranasal insulin vs. placebo on cognition and regional perfusion and vasoreactivity to CO2 challenge measured by 3-D continuous arterial spin labeling (CASL) MRI at 3 Tesla in the control and diabetic groups.
Cognitive outcome: Brief Visuospatial Spatial Memory test -Total Recall (unit T Score).
Perfusion outcome: Regional vasoreactivity (ml/100g/min/mmHg).
Each participant received a single dose of intranasal insulin (INI) or placebo on day 2 and a single dose dose of insulin or placebo on day 3 in a random order.
Acute effects on baseline perfusion, regional vasoreactivity and cognition were determined within 2 hours after administration of insulin or placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perfusion Outcome: Right Insular Cortex Perfusion (ml/100g/Min/mmHg)</measure>
    <time_frame>Acute changes within 2 hours</time_frame>
    <description>To determine the acute effects of a single 40-IU dose of intranasal insulin vs. placebo on cognition and regional perfusion and vasoreactivity to CO2 challenge measured by 3-D continuous arterial spin labeling (CASL) MRI at 3 Tesla in the control and diabetic groups.
Cognitive outcome: Brief Visuospatial Spatial Memory test -Total Recall (unit T Score).
Perfusion outcome: Regional vasoreactivity (ml/100g/min/mmHg).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Insulin vs. placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy vs. Diabetic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal insulin</intervention_name>
    <description>The acute effects of a single 40-IU dose of intranasal insulin</description>
    <arm_group_label>Insulin vs. placebo</arm_group_label>
    <arm_group_label>Healthy vs. Diabetic</arm_group_label>
    <other_name>Novolin R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The acute effects of intranasal sterile saline.</description>
    <arm_group_label>Insulin vs. placebo</arm_group_label>
    <arm_group_label>Healthy vs. Diabetic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diabetes group:

          -  30 men and women aged &gt;50 years old diagnosed with T2DM and treated &gt; 5 years with
             oral agents

          -  Diabetes severity will be assessed from diabetes duration, hemoglobin A1C, and fasting
             glucose levels.

        Control group:

          -  30 healthy men and women aged &gt;50 years selected to have the same age and sex
             distributions as the diabetic subjects

          -  Normotensive, not treated for any systemic disease, and have normal fasting blood
             glucose.

        Exclusion Criteria:

          -  Type 1 Diabetes Mellitus

          -  History of severe hypoglycemia or hypoglycemic episode during home baseline monitoring

          -  Positive stress test for CAD or other ischemic conditions

          -  Carotid stenosis &gt; 50% by medical history

          -  History of a clinically documented stroke

          -  Treatment with any medications administered intranasally including intranasal steroids

          -  Any previous adverse or allergic reactions to insulin

          -  Acute or unstable medical condition including Myocardial infarction or major illness
             and surgery within six months

          -  Liver or renal failure or transplant

          -  Uncontrolled hypertension (systolic BP &gt;180 and/or diastolic BP &gt;100 mm Hg or subjects
             taking more than 3 antihypertensive medications)

          -  Seizure disorders

          -  Malignant tumors

          -  Clinical dementia (by history) or inability to follow details of the protocol(MMSE
             (Mini Mental Status Exam) score (≥3 points below the Comparative Normal Value for the
             subject's age group and education level, or ≤ 24)

          -  Current recreational drug or alcohol abuse

          -  Morbid obesity (BMI &gt;40)

          -  Inability to obtain permission for participation from the primary care physician

          -  Transcranial Doppler (TCD) exclusion criterion - poor insonation window and TCD signal

          -  MR exclusion criteria - any metal or bioimplants not compatible with 3 Tesla MRI and
             claustrophobia

          -  Clinically significant and movement limiting hip, knee and/or back disorders or
             injury, and rheumatoid arthritis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vera Novak, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center, Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Novak V, Milberg W, Hao Y, Munshi M, Novak P, Galica A, Manor B, Roberson P, Craft S, Abduljalil A. Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes. Diabetes Care. 2014;37(3):751-9. doi: 10.2337/dc13-1672. Epub 2013 Oct 7.</citation>
    <PMID>24101698</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang H, Hao Y, Manor B, Novak P, Milberg W, Zhang J, Fang J, Novak V. Intranasal insulin enhanced resting-state functional connectivity of hippocampal regions in type 2 diabetes. Diabetes. 2015 Mar;64(3):1025-34. doi: 10.2337/db14-1000. Epub 2014 Sep 23.</citation>
    <PMID>25249577</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2010</study_first_submitted>
  <study_first_submitted_qc>September 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2010</study_first_posted>
  <results_first_submitted>July 24, 2014</results_first_submitted>
  <results_first_submitted_qc>October 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 28, 2014</results_first_posted>
  <last_update_submitted>October 28, 2014</last_update_submitted>
  <last_update_submitted_qc>October 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Vera Novak</investigator_full_name>
    <investigator_title>MD PhD, Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>diabetes, blood flow, brain perfusion, cognitive function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Thirty consented subjects, 15 type 2 diabetic and 14 controls completed the protocol. One control was excluded after starting the study. Screened participants that did not start study: 27 were excluded after screening visit, 7 withdrew consent. Enrollment Table list the characteristics of 29 participants who completed the protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Diabetes Group: Placebo First</title>
          <description>Comparisons of acute effects of intranasal insulin or placebo on cerebral blood flow and cognition.
Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo</description>
        </group>
        <group group_id="P2">
          <title>Diabetes Group: Insulin First</title>
          <description>Comparisons of acute effects of intranasal insulin or placebo on cerebral blood flow and cognition.
Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo</description>
        </group>
        <group group_id="P3">
          <title>Control Group: Placebo First</title>
          <description>Comparisons of acute effects of intranasal insulin or placebo on cerebral blood flow and cognition.
Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo</description>
        </group>
        <group group_id="P4">
          <title>Control Group: Insulin First</title>
          <description>Comparisons of acute effects of intranasal insulin or placebo on cerebral blood flow and cognition.
Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Twenty nine consented subjects, 15 type 2 diabetic and 14 controls completed the protocol.</population>
      <group_list>
        <group group_id="B1">
          <title>Healthy</title>
          <description>Comparisons of acute effects of intranasal insulin or placebo on cerebral blood flow and cognition.
Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo ( sterilesaline) in type 2 diabetes and the non-diabetic control group.Each participant received a single dose of insulin and a single dose of placebo on 2 consequent days in random order.</description>
        </group>
        <group group_id="B2">
          <title>Diabetics</title>
          <description>Comparisons of acute effects of intranasal insulin or placebo on cerebral blood flow and cognition.
Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo ( sterilesaline) in type 2 diabetes and the non-diabetic control group.Each participant received a single dose of insulin and a single dose of placebo on 2 consequent days in random order.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.1" spread="9.9"/>
                    <measurement group_id="B2" value="62.0" spread="7.9"/>
                    <measurement group_id="B3" value="61.1" spread="8.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cognitive Outcome: Brief Visuospatial Spatial Memory Test -Total Recall (Unit T Score)</title>
        <description>To determine the acute effects of a single 40-IU dose of intranasal insulin vs. placebo on cognition and regional perfusion and vasoreactivity to CO2 challenge measured by 3-D continuous arterial spin labeling (CASL) MRI at 3 Tesla in the control and diabetic groups.
Cognitive outcome: Brief Visuospatial Spatial Memory test -Total Recall (unit T Score).
Perfusion outcome: Regional vasoreactivity (ml/100g/min/mmHg).
Each participant received a single dose of intranasal insulin (INI) or placebo on day 2 and a single dose dose of insulin or placebo on day 3 in a random order.
Acute effects on baseline perfusion, regional vasoreactivity and cognition were determined within 2 hours after administration of insulin or placebo.</description>
        <time_frame>Acute changes within 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diabetes Group: Placebo</title>
            <description>Comparisons of acute effects of intranasal insulin or placebo on cerebral blood flow and cognition.
Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo in type 2 diabetes and the control group on cognitive function (Brief Visuospatial Memory test-Revised (BVMT-R)).</description>
          </group>
          <group group_id="O2">
            <title>Diabetes Group: Insulin</title>
            <description>Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo in type 2 diabetes and the control group.</description>
          </group>
          <group group_id="O3">
            <title>Control Group: Placebo</title>
            <description>Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo in type 2 diabetes and the control group on cognitive function (Brief Visuospatial Memory test-Revised (BVMT-R)).</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Insulin</title>
            <description>Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo in type 2 diabetes and the control group on cognitive function (Brief Visuospatial Memory test-Revised (BVMT-R)).</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Outcome: Brief Visuospatial Spatial Memory Test -Total Recall (Unit T Score)</title>
          <description>To determine the acute effects of a single 40-IU dose of intranasal insulin vs. placebo on cognition and regional perfusion and vasoreactivity to CO2 challenge measured by 3-D continuous arterial spin labeling (CASL) MRI at 3 Tesla in the control and diabetic groups.
Cognitive outcome: Brief Visuospatial Spatial Memory test -Total Recall (unit T Score).
Perfusion outcome: Regional vasoreactivity (ml/100g/min/mmHg).
Each participant received a single dose of intranasal insulin (INI) or placebo on day 2 and a single dose dose of insulin or placebo on day 3 in a random order.
Acute effects on baseline perfusion, regional vasoreactivity and cognition were determined within 2 hours after administration of insulin or placebo.</description>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.46" spread="8.86"/>
                    <measurement group_id="O2" value="41.23" spread="9.85"/>
                    <measurement group_id="O3" value="43.1" spread="17.29"/>
                    <measurement group_id="O4" value="50.9" spread="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Perfusion Outcome: Right Insular Cortex Perfusion (ml/100g/Min/mmHg)</title>
        <description>To determine the acute effects of a single 40-IU dose of intranasal insulin vs. placebo on cognition and regional perfusion and vasoreactivity to CO2 challenge measured by 3-D continuous arterial spin labeling (CASL) MRI at 3 Tesla in the control and diabetic groups.
Cognitive outcome: Brief Visuospatial Spatial Memory test -Total Recall (unit T Score).
Perfusion outcome: Regional vasoreactivity (ml/100g/min/mmHg).</description>
        <time_frame>Acute changes within 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diabetes Group: Placebo</title>
            <description>Comparisons of acute effects of intranasal insulin or placebo on cerebral blood flow and cognition.
Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo in type 2 diabetes and the control group on cognitive function (Brief Visuospatial Memory test-Revised (BVMT-R)).</description>
          </group>
          <group group_id="O2">
            <title>Diabetes Group: Insulin</title>
            <description>Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo in type 2 diabetes and the control group.</description>
          </group>
          <group group_id="O3">
            <title>Control Group: Placebo</title>
            <description>Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo in type 2 diabetes and the control group on cognitive function (Brief Visuospatial Memory test-Revised (BVMT-R)).</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Insulin</title>
            <description>Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo in type 2 diabetes and the control group on cognitive function (Brief Visuospatial Memory test-Revised (BVMT-R)).</description>
          </group>
        </group_list>
        <measure>
          <title>Perfusion Outcome: Right Insular Cortex Perfusion (ml/100g/Min/mmHg)</title>
          <description>To determine the acute effects of a single 40-IU dose of intranasal insulin vs. placebo on cognition and regional perfusion and vasoreactivity to CO2 challenge measured by 3-D continuous arterial spin labeling (CASL) MRI at 3 Tesla in the control and diabetic groups.
Cognitive outcome: Brief Visuospatial Spatial Memory test -Total Recall (unit T Score).
Perfusion outcome: Regional vasoreactivity (ml/100g/min/mmHg).</description>
          <units>ml/100g/min/mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" spread="3.3"/>
                    <measurement group_id="O2" value="46.4" spread="3.6"/>
                    <measurement group_id="O3" value="40.3" spread="2.4"/>
                    <measurement group_id="O4" value="36.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Diabetes Group: Placebo</title>
          <description>Comparisons of acute effects of intranasal insulin or placebo on cerebral blood flow and cognition.
Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo in type 2 diabetes and the non-diabetic control group.
The intranasal administration of insulin was safe, with no serious adverse events or hypoglycemic episodes and the protocol was feasible for participants.</description>
        </group>
        <group group_id="E2">
          <title>Diabetes Group: Insulin</title>
          <description>Comparisons of acute effects of intranasal insulin or placebo on cerebral blood flow and cognition.
Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo in type 2 diabetes and the non-diabetic control group.
The intranasal administration of insulin was safe, with no serious adverse events or hypoglycemic episodes and the protocol was feasible for participants.</description>
        </group>
        <group group_id="E3">
          <title>Control Group: Placebo</title>
          <description>Comparisons of acute effects of intranasal insulin or placebo on cerebral blood flow and cognition.
Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo in type 2 diabetes and the non-diabetic control group.
The intranasal administration of insulin was safe, with no serious adverse events or hypoglycemic episodes and the protocol was feasible for participants.</description>
        </group>
        <group group_id="E4">
          <title>Control Group: Insulin</title>
          <description>Comparisons of acute effects of intranasal insulin or placebo on cerebral blood flow and cognition.
Intranasal insulin: The acute effects of a single 40-IU dose of intranasal insulin vs. placebo in type 2 diabetes and the non-diabetic control group.
The intranasal administration of insulin was safe, with no serious adverse events or hypoglycemic episodes and the protocol was feasible for participants.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Cardiac disorders</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Healthy-Insulin : One control subject was identified to have un-diagnosed hypertension prior and after intranasal insulin administration.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Vera Novak</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617-632-8680</phone>
      <email>vnovak@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

